Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "poly(ADP-ribose) polymerase (PARP)" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Inhibition of poly(ADP-ribose) polymerase activity affects its subcellular localization and DNA strand break rejoining
Autorzy:
Ryabokon, Nadezhda
Cieślar-Pobuda, Artur
Rzeszowska-Wolny, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1040571.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
DNA strand break rejoining
efficiency of PARP inhibition
PARP foci
poly(ADP-ribose) polymerase (PARP)
PARP inhibitors
Opis:
Poly(ADP-ribose) polymerase (PARP) plays a crucial role in DNA repair. Modulation of its activity by stimulation or inhibition is considered as a potentially important strategy in clinical practice, especially to sensitize tumor cells to chemo- and radiotherapy through inhibition of DNA repair. Here we studied the effect of the three PARP inhibitors, 5-iodo-6-amino-benzopyrone (INH2BP), 1,5-isoquinolinediol (1,5-dihydroxyisoquinolinediol (1,5-IQD) and 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025), and for two of them the efficiency in slowing the rejoining of DNA strand breaks induced by H2O2 was compared. Inhibition of PARP changed its intranuclear localization markedly; cells exposed to the inhibitor NU1025 showed a significant tendency to accumulate PARP in large foci, whereas in untreated cells its distribution was more uniform. The speed and efficiency of rejoining of H2O2-induced DNA strand breaks were lower in cells incubated with a PARP inhibitor, and the kinetics of rejoining were modulated in a different manner by each inhibitor. At a concentration of 100 µM the efficiency of the inhibitors could be ranked in the order NU1025 > IQD > INH2BP. The two first compounds were able to decrease the overall PARP activity below the level detected in control cells, while INH2BP showed up to 40% PARP activity after exposure to H2O2.
Źródło:
Acta Biochimica Polonica; 2009, 56, 2; 243-248
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Poly(adP-ribose) polymerase inhibitor olaparib in the treatment of ovarian cancer: a comprehensive review of current literature
Autorzy:
Poboży, Kamil
Domańska, Julia
Domański, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/22792529.pdf
Data publikacji:
2023-07-02
Wydawca:
Medical Education
Tematy:
Olaparib
PARP inhibitor
ovarian cancer
targeted therapy
poly(ADP-ribose) polymerase
cancer therapy
Opis:
Purpose of the review: This comprehensive review aims to provide a summary of current research on the utilization of olaparib, a poly(ADP-ribose) polymerase (PArP) inhibitor, in the treatment of ovarian cancer. The review aims to highlight the key findings from recent clinical trials and assess the potential of olaparib as a targeted therapy for improving the prognosis of ovarian cancer patients. recent findings: Ovarian cancer remains a significant global health concern with high mortality rates. While optimal debulking surgery and platinum-based chemotherapy are the standard treatments, the recurrence rates remain substantial. The emergence of PArP inhibitors, particularly olaparib, has intro duced a novel therapeutic approach that targets the genomic instability and DnA repair mechanisms in cancer cells. notable clinical trials, such as SOl O1, SOl O2, and PAOlA-1, have demonstrated the effectiveness of olaparib in significantly improving progression-free survival, particularly in patients with Br CA mutations or homologous recombination deficiency. Additionally, combination therapies involving olaparib, such as those with bevacizumab or entinostat, have shown promising results. Summary: The utilization of olaparib has brought about a paradigm shift in the treatment of ovarian cancer. notably, it has shown significant improvements in progression-free survival and overall survival, particularly in patients with Br CA mutations or homologous recombination deficiency. The exploration of olaparib through various clinical trials and combination therapies continues to provide valuable insights and offer new prospects for ovarian cancer patients. Moreover, the growing understanding of PArP inhibitors holds the potential for further advancements in the prognosis of patients with this formidable condition.
Źródło:
OncoReview; 2023, 13, 2; 39-47
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies